Literature DB >> 20854021

Replication of Clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, in Aedes and Culex mosquitoes.

Sara Moutailler1, Ghazi Krida, Yoann Madec, Michèle Bouloy, Anna-Bella Failloux.   

Abstract

Rift Valley fever virus continues to cause large outbreaks of acute and febrile illness among humans and domestic animals in Africa. The high pathogenicity of the virus is mainly due to the non-structural protein derived from the S segment NSs, which was shown to inhibit the type I interferon expression at the transcriptional level and to suppress host cell RNA synthesis. Clone 13, a naturally attenuated clone containing a deletion of 70% in NSs, is a promising vaccine candidate as it has no pathogenicity for mice and is highly immunogenic leading to long-lasting immunity. If Clone 13 succeeds in inducing a transient viremia in inoculated animals, is a mosquito vector able to replicate Clone 13 and is the vector affected by viral infection? In this work, we orally infected two mosquito species, Aedes vexans and Culex pipiens quinquefasciatus, with the avirulent Clone 13. We showed that the mosquito Ae. vexans better replicated the avirulent Clone 13 than Cx. p. quinquefasciatus. Moreover, infection with Clone 13 did not cause any important changes in mosquito's life-history traits compared to noninfected females. Nevertheless, it is likely that Clone 13 would not be efficiently transmitted by mosquito vectors.

Entities:  

Mesh:

Year:  2010        PMID: 20854021     DOI: 10.1089/vbz.2009.0246

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  9 in total

1.  Insecticide resistance genes affect Culex quinquefasciatus vector competence for West Nile virus.

Authors:  Célestine M Atyame; Haoues Alout; Laurence Mousson; Marie Vazeille; Mawlouth Diallo; Mylène Weill; Anna-Bella Failloux
Journal:  Proc Biol Sci       Date:  2019-01-16       Impact factor: 5.349

Review 2.  Vector Competence of Mediterranean Mosquitoes for Rift Valley Fever Virus: A Meta-Analysis.

Authors:  Alex Drouin; Véronique Chevalier; Benoit Durand; Thomas Balenghien
Journal:  Pathogens       Date:  2022-04-23

3.  Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

4.  Discovery of a unique novel clade of mosquito-associated bunyaviruses.

Authors:  Marco Marklewitz; Florian Zirkel; Innocent B Rwego; Hanna Heidemann; Pascal Trippner; Andreas Kurth; René Kallies; Thomas Briese; W Ian Lipkin; Christian Drosten; Thomas R Gillespie; Sandra Junglen
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

5.  Role of Bunyamwera Orthobunyavirus NSs protein in infection of mosquito cells.

Authors:  Agnieszka M Szemiel; Anna-Bella Failloux; Richard M Elliott
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

6.  Culex pipiens, an experimental efficient vector of West Nile and Rift Valley fever viruses in the Maghreb region.

Authors:  Fadila Amraoui; Ghazi Krida; Ali Bouattour; Adel Rhim; Jabeur Daaboub; Zoubir Harrat; Said-Chawki Boubidi; Mhamed Tijane; Mhammed Sarih; Anna-Bella Failloux
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

7.  Transmission of Rift Valley fever virus from European-breed lambs to Culex pipiens mosquitoes.

Authors:  Rianka P M Vloet; Chantal B F Vogels; Constantianus J M Koenraadt; Gorben P Pijlman; Martin Eiden; Jose L Gonzales; Lucien J M van Keulen; Paul J Wichgers Schreur; Jeroen Kortekaas
Journal:  PLoS Negl Trop Dis       Date:  2017-12-27

8.  Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection.

Authors:  Mary B Crabtree; Rebekah J Kent Crockett; Brian H Bird; Stuart T Nichol; Bobbie Rae Erickson; Brad J Biggerstaff; Kalanthe Horiuchi; Barry R Miller
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01

Review 9.  Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile.

Authors:  Thomas P Monath; Jeroen Kortekaas; Douglas M Watts; Rebecca C Christofferson; Angelle Desiree LaBeaud; Brian Gowen; Clarence J Peters; Darci R Smith; Robert Swanepoel; John C Morrill; Thomas G Ksiazek; Phillip R Pittman; Brian H Bird; George Bettinger
Journal:  Vaccine X       Date:  2020-04-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.